an EORTC-NCI-AACR session, haven't looked at it......
Wednesday 20 November 2002
Poster session: Prodrugs
Poster Boddy, Alan Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a Phase I study.
Poster Pegram, M. Enzyme-Catalyzed Therapeutic Activation (ECTA) NB1011 (Thymectacin™) selectively targets thymidylate synthase (TS) - overexpressing tumor cells: preclinical and phase I clinical results
Poster Kavanagh, John Phase 2 Study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer
Poster Rosen, Lee Phase II Study of TLK286 (Glutathione Analog Activated by GST P1-1) in refractory colorectal cancer
Poster Keck, James Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines
Poster Baumgartner, Christian Ethanolatoamine platinum chelates as prodrugs which are selectively activated in slightly acidic environment
Poster Kassis, Amin Enzyme-mediated insolubilization therapy
Poster Mhaka, Annastasiah Enzymatic activation of prodrugs by prostate-specific membrane antigen (PSMA)
Poster Borgford, Thor Elaboration of synergy between the prodrugs TST220 and TST334 and conventional chemotherapeutics |
